Cancer Therapeutics signs deal with Duke University
This article was originally published in Scrip
Executive Summary
The Australian company Cancer Therapeutics has signed an agreement with Duke University in the US to discover and develop new drugs for the treatment of different forms of cancer. The agreement will be based on the work of Duke's Professor Patrick Casey, who has been investigating lipid signalling pathways and the role of lipid metabolising enzymes in cancer and has developed a series of new inhibitors for these. Cancer Therapeutics is to begin a drug development programme to bring these early-stage compounds towards the clinic.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.